Company intelligence / Profile preview

Neuronascent

Clarksville, Maryland, USAneuronascent.com ↗

Ownership: Private
Development stage: Other

Overview

Neuronascent has developed a proprietary small molecule-based platform to promote adult neurogenesis and neuronal survival. Their lead candidate, NNI‑362, has completed Phase 1a trials demonstrating safety in healthy aged subjects. The company aims to advance into patient studies for mild-to-moderate Alzheimer’s disease and early Parkinson's disease. Preclinical data show efficacy in animal models of chronic neurodegenerative diseases, with the potential to reverse or halt progression by regenerating functional neurons.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

4 assets

nni-362

3 more assets in the full pipeline.

Partnerships

ChemRar Pharma – collaboration on screening developmental pathway inhibitors using Neuronascent’s neurogenesis platform for co-development opportunities.

Beyond the preview

Go deeper on Neuronascent.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuronascent.